Cidara Therapeutics (CDTX) News Today $11.44 -0.11 (-0.95%) (As of 09/6/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 Time Period September 5 at 8:00 AM | globenewswire.comCidara to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceAugust 19, 2024 | globenewswire.comCidara Therapeutics Announces Appointment of Jim Beitel as Chief Business OfficerAugust 18, 2024 | marketbeat.comCidara Therapeutics, Inc. (NASDAQ:CDTX) Short Interest UpdateCidara Therapeutics, Inc. (NASDAQ:CDTX - Get Free Report) was the recipient of a large decrease in short interest in the month of July. As of July 31st, there was short interest totalling 100,700 shares, a decrease of 11.7% from the July 15th total of 114,000 shares. Based on an average daily trading volume, of 38,500 shares, the days-to-cover ratio is presently 2.6 days. Currently, 1.5% of the shares of the company are short sold.August 16, 2024 | msn.comHC Wainwright & Co. Upgrades Cidara Therapeutics (CDTX)August 15, 2024 | marketbeat.comCidara Therapeutics, Inc. (NASDAQ:CDTX) Expected to Post Q1 2025 Earnings of ($4.66) Per ShareCidara Therapeutics, Inc. (NASDAQ:CDTX - Free Report) - Research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Cidara Therapeutics in a research note issued on Wednesday, August 14th. HC Wainwright analyst E. Arce forecasts that the biotechnology companAugust 14, 2024 | finanznachrichten.deCidara Therapeutics, Inc.: Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial ResultsAugust 14, 2024 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Stock Rating Reaffirmed by Cantor FitzgeraldCantor Fitzgerald reiterated an "overweight" rating on shares of Cidara Therapeutics in a report on Wednesday.August 13, 2024 | globenewswire.comCidara Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial ResultsAugust 13, 2024 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Shares Pass Below 50-Day Moving Average of $12.22Cidara Therapeutics (NASDAQ:CDTX) Stock Price Passes Below 50 Day Moving Average of $12.22August 3, 2024 | marketbeat.comCidara Therapeutics, Inc. (NASDAQ:CDTX) Receives Consensus Rating of "Buy" from BrokeragesShares of Cidara Therapeutics, Inc. (NASDAQ:CDTX - Get Free Report) have received an average rating of "Buy" from the four ratings firms that are currently covering the company, MarketBeat.com reports. Three equities research analysts have rated the stock with a buy rating and one has given a stroJuly 31, 2024 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Shares Cross Above Fifty Day Moving Average of $12.27Cidara Therapeutics (NASDAQ:CDTX) Stock Price Passes Above 50 Day Moving Average of $12.27July 17, 2024 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Stock Price Passes Above Fifty Day Moving Average of $12.23Cidara Therapeutics (NASDAQ:CDTX) Stock Crosses Above 50-Day Moving Average of $12.23July 3, 2024 | marketbeat.comShort Interest in Cidara Therapeutics, Inc. (NASDAQ:CDTX) Rises By 5.8%Cidara Therapeutics, Inc. (NASDAQ:CDTX - Get Free Report) was the target of a significant increase in short interest in the month of June. As of June 15th, there was short interest totalling 113,600 shares, an increase of 5.8% from the May 31st total of 107,400 shares. Currently, 2.6% of the shares of the company are sold short. Based on an average trading volume of 74,900 shares, the days-to-cover ratio is presently 1.5 days.July 3, 2024 | globenewswire.comCidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 20, 2024 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Given "Overweight" Rating at Cantor FitzgeraldCantor Fitzgerald restated an "overweight" rating on shares of Cidara Therapeutics in a research note on Thursday.June 16, 2024 | marketbeat.comCidara Therapeutics, Inc. (NASDAQ:CDTX) Sees Large Increase in Short InterestCidara Therapeutics, Inc. (NASDAQ:CDTX - Get Free Report) was the target of a significant increase in short interest in May. As of May 31st, there was short interest totalling 107,400 shares, an increase of 53.2% from the May 15th total of 70,100 shares. Approximately 2.5% of the shares of the stock are short sold. Based on an average daily volume of 70,600 shares, the days-to-cover ratio is presently 1.5 days.June 14, 2024 | marketbeat.comCidara Therapeutics, Inc. (NASDAQ:CDTX) Given Average Recommendation of "Buy" by BrokeragesShares of Cidara Therapeutics, Inc. (NASDAQ:CDTX - Get Free Report) have earned an average recommendation of "Buy" from the four analysts that are covering the company, Marketbeat.com reports. Three investment analysts have rated the stock with a buy recommendation and one has given a strong buy rJune 12, 2024 | insidertrades.comCidara Therapeutics, Inc. (NASDAQ:CDTX) CEO Purchases $105,680.00 in StockJune 2, 2024 | marketbeat.comCidara Therapeutics, Inc. (NASDAQ:CDTX) Short Interest Down 16.2% in MayCidara Therapeutics, Inc. (NASDAQ:CDTX - Get Free Report) was the recipient of a significant decline in short interest during the month of May. As of May 15th, there was short interest totalling 70,100 shares, a decline of 16.2% from the April 30th total of 83,700 shares. Currently, 1.7% of the shares of the stock are short sold. Based on an average trading volume of 67,000 shares, the short-interest ratio is currently 1.0 days.May 30, 2024 | globenewswire.comCidara Therapeutics to Present Preclinical Data on CD388 at ASM Microbe 2024 ConferenceMay 29, 2024 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Shares Pass Below Fifty Day Moving Average of $14.59Cidara Therapeutics (NASDAQ:CDTX) Stock Passes Below Fifty Day Moving Average of $14.59May 16, 2024 | markets.businessinsider.comBuy Rating Justified by Cidara Therapeutics’ Upcoming Clinical Trials and Expanding Oncology PipelineMay 16, 2024 | finanznachrichten.deCidara Therapeutics, Inc.: Cidara Therapeutics Regains Compliance with Nasdaq Continued Listing RulesMay 16, 2024 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Receives "Buy" Rating from Needham & Company LLCNeedham & Company LLC reiterated a "buy" rating and set a $25.00 target price on shares of Cidara Therapeutics in a report on Thursday.May 16, 2024 | msn.comCDTX Stock Earnings: Cidara Therapeutics Misses EPS, Misses Revenue for Q1 2024May 15, 2024 | stockhouse.comROSEN, A LEADING NATIONAL FIRM, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTXMay 15, 2024 | sfgate.comCidara Therapeutics: Q1 Earnings SnapshotMay 15, 2024 | globenewswire.comCidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial ResultsMay 15, 2024 | globenewswire.comCidara Therapeutics Regains Compliance with Nasdaq Continued Listing RulesMay 10, 2024 | prnewswire.comCDTX INVESTOR NOTICE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTXApril 26, 2024 | finanznachrichten.deCidara Therapeutics, Inc.: Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024April 26, 2024 | finance.yahoo.comCidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024April 25, 2024 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Shares Gap Up on Analyst UpgradeCidara Therapeutics (NASDAQ:CDTX) Shares Gap Up on Analyst UpgradeApril 25, 2024 | marketbeat.comWBB Securities Reaffirms "Strong-Buy" Rating for Cidara Therapeutics (NASDAQ:CDTX)WBB Securities reissued a "strong-buy" rating and set a $40.00 price target on shares of Cidara Therapeutics in a report on Thursday.April 25, 2024 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) PT Raised to $25.00 at Needham & Company LLCNeedham & Company LLC increased their target price on Cidara Therapeutics from $3.00 to $25.00 and gave the company a "buy" rating in a report on Thursday.April 25, 2024 | businesswire.comCDTX LOSS ALERT: ROSEN, A LEADING LAW FIRM, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – CDTXApril 24, 2024 | msn.comCidara Therapeutics shares surge 30% after reacquiring flu treatmentApril 24, 2024 | marketwatch.comCidara Therapeutics To Sell Candidiasis Treatment, Re-acquire Flu AssetApril 24, 2024 | msn.comCidara stock rallies amid $240M private placement, drug updateApril 24, 2024 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Shares Up 7.1%Cidara Therapeutics (NASDAQ:CDTX) Shares Up 7.1%April 24, 2024 | globenewswire.comCidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 MillionApril 24, 2024 | globenewswire.comCidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC PipelineApril 24, 2024 | marketbeat.comTrading was temporarily halted for "CDTX" at 07:04 PM with a stated reason of "News pending."April 23, 2024 | finanznachrichten.deCidara Therapeutics, Inc.: Cidara Therapeutics Announces Receipt of Nasdaq Delinquency NoticeApril 23, 2024 | finanznachrichten.deCidara Therapeutics, Inc.: Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsApril 23, 2024 | marketbeat.comCantor Fitzgerald Reiterates "Overweight" Rating for Cidara Therapeutics (NASDAQ:CDTX)Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Cidara Therapeutics in a research report on Tuesday.April 22, 2024 | investorplace.comCDTX Stock Earnings: Cidara Therapeutics Beats EPS, Beats Revenue for Q4 2023April 22, 2024 | msn.comWhy Cidara Therapeutics (CDTX) Stock Is FallingApril 22, 2024 | globenewswire.comCidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsApril 22, 2024 | globenewswire.comCidara Therapeutics Announces Receipt of Nasdaq Delinquency Notice Get Cidara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CDTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Pre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳 (Ad)45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A investment now open. Claim Exclusive 100% Bonus: $0.25/Share CDTX Media Mentions By Week CDTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CDTX News Sentiment▼0.000.55▲Average Medical News Sentiment CDTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CDTX Articles This Week▼12▲CDTX Articles Average Week Get Cidara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CDTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: SCYNEXIS News Today Curis News Today X4 Pharmaceuticals News Today Genfit News Today Tenaya Therapeutics News Today Molecular Partners News Today Eliem Therapeutics News Today Inhibrx News Today Candel Therapeutics News Today Gossamer Bio News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CDTX) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cidara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cidara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.